Pompano Beach, FL -- (SBWIRE) -- 01/11/2013 -- Csrnewsdaily.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following Tuesday’s Top Gainers:-
GeoGlobal Resources Inc. (NYSE:GGR) is currently trading at $0.0599,7.85% lower. GeoGlobal Resources Inc. is an exploration-stage company. The Company is engaged, through the Company's subsidiaries, in the exploration for and development of oil and natural gas reserves. As of December 31, 2011, the Company's activities were being undertaken in four geological basins located offshore and onshore in India, one geological basin located offshore in Israel and one geological basin located onshore in Colombia.
Can GGR Continue To Move Higher? Find Out Here
Houston American Energy Corporation (NYSE:HUSA) is higher 14.43% to $0.310. Houston American Energy Corp (Houston American) is an independent oil and gas company focused on the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties in the United States Gulf Coast region and in South America. The Company’s oil and gas reserves and operations are concentrated in the South American country of Colombia and in the onshore Gulf Coast region, particularly Texas and Louisiana.
Can HUSA Extend Rally? Find Out Here
Cheniere Energy, Inc. (NYSE:LNG) fell 1.70% to $20.19. Cheniere Energy, Inc., formerly known as Bexy Communications, Inc., is a United States-based energy company, which is engaged in liquefied natural gas (LNG) related businesses. The Company owns and operates the Sabine Pass LNG terminal and Creole Trail pipeline in Louisiana. It develops a network of three onshore LNG receiving terminals and related natural gas pipelines along the United States Gulf Coast.
How Should Investors Trade LNG Now? Find Out Here
Hemispherx BioPharma, Inc (NYSE:HEB) among the losers and the stock fell 3.10% to $0.281. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
How Should Investors React To HEB Now? Find Out Here
North American Palladium Ltd (USA) (NYSE:PAL) fell 3.59% to $1.61. North American Palladium Ltd. (NAP) is a precious metals producer that has been operating its flagship Lac des Iles mine (LDI) located in Ontario, Canada. NAP also operates the Vezza gold mine located in the Abitibi region of Quebec. The Company is in the business of exploring and mining palladium, platinum, gold and certain base metals. NAP operates in three segments: palladium operations include the LDI palladium mine and mill; gold operations include the Sleeping Giant gold mine and mill; and corporate and other.
How Should Investors React To PAL Now? Find Out Here
About Csrnewsdaily.com
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
Disclaimer
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contact:
Csrnewsdaily.com
info@csrnewsdaily.com
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)